VBI Vaccines, Inc. - Company Profile (NASDAQ:VBIV)

About VBI Vaccines, Inc. -

VBI Vaccines, Inc. - logoVBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VBIV
  • CUSIP:
Key Metrics:
  • Previous Close: $4.78
  • 50 Day Moving Average: $3.87
  • 200 Day Moving Average: $3.50
  • 52-Week Range: $2.75 - $5.23
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.29
  • P/E Growth: 0.00
  • Market Cap: $173.90M
  • Outstanding Shares: 36,380,000
Additional Links:
Companies Related to VBI Vaccines, Inc. -:

Analyst Ratings

Consensus Ratings for VBI Vaccines, Inc. - (NASDAQ:VBIV) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (25.52% upside)

Analysts' Ratings History for VBI Vaccines, Inc. - (NASDAQ:VBIV)
Show:
DateFirmActionRatingPrice TargetDetails
10/10/2016LaidlawInitiated CoverageBuy$6.00View Rating Details
7/26/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuyView Rating Details
5/7/2015Noble FinancialInitiated CoverageBuy$7.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for VBI Vaccines, Inc. - (NASDAQ:VBIV)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for VBI Vaccines, Inc. - (NASDAQ:VBIV)
Current Year EPS Consensus Estimate: $-0.67 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS

Dividends

Dividend History for VBI Vaccines, Inc. - (NASDAQ:VBIV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for VBI Vaccines, Inc. - (NASDAQ:VBIV)
Insider Ownership Percentage: 54.50%
Institutional Ownership Percentage: 22.11%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/6/2016Perceptive Advisors LlcMajor ShareholderBuy3,383,955$3.05$10,321,062.75View SEC Filing  
8/14/2015Perceptive Advisors LlcMajor ShareholderBuy650,000$2.08$1,352,000.00View SEC Filing  
9/30/2013Murray George SmithCFOBuy3,027$1.13$3,420.51View SEC Filing  
8/21/2013Murray George SmithCFOBuy8,973$1.17$10,498.41View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for VBI Vaccines, Inc. - (NASDAQ:VBIV)
DateHeadline
streetinsider.com logoVBI Vaccines (VBIV) Announces Positive Response from Health Canada's Initial Evaluation of Sci-B-Vac Phase III Clinical Program (NASDAQ:VBIV)
www.streetinsider.com - February 23 at 3:06 AM
finanznachrichten.de logoVBI VACCINES INC (NASDAQ:VBIV)
www.finanznachrichten.de - February 23 at 3:06 AM
us.rd.yahoo.com logoVBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program (NASDAQ:VBIV)
us.rd.yahoo.com - February 22 at 10:46 AM
investing.com logoHere's Why The Latest VBI Vaccines Announcement Is Important (NASDAQ:VBIV)
www.investing.com - February 17 at 5:57 AM
News IconVBI Vaccines, Inc. (VBIV) Gets European Support For Pivotal Phase III Sci-B-Vac Trial (NASDAQ:VBIV)
feedproxy.google.com - February 14 at 1:24 PM
marketwired.com logoVBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac™ Phase III Clinical Study (NASDAQ:VBIV)
www.marketwired.com - February 8 at 1:51 AM
us.rd.yahoo.com logoVBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study (NASDAQ:VBIV)
us.rd.yahoo.com - February 7 at 3:49 PM
finance.yahoo.com logoVBIV: Notable Investors and Multiple Upcoming Catalysts Make VBIV a Stock to Watch in 2017 (NASDAQ:VBIV)
finance.yahoo.com - February 3 at 6:35 AM
News IconVBI Vaccines Inc VBIV Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:VBIV)
www.bioportfolio.com - January 30 at 10:17 AM
insidermonkey.com logo$23.6M Investment From 2015’s Top Performing Hedge Fund Makes VBI Vaccines, Inc. (VBIV) Even More Undervalued (NASDAQ:VBIV)
www.insidermonkey.com - December 6 at 8:04 PM
us.rd.yahoo.com logoVBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors (NASDAQ:VBIV)
us.rd.yahoo.com - December 6 at 11:45 AM
us.rd.yahoo.com logo8:42 am VBI Vaccines completes sale of 3.475 mln common shares at $3.05/share in a private placement to Perceptive Advisors, for total gross proceeds of approx. $10.6 mln; co also announced $13 mln in secured debt (NASDAQ:VBIV)
us.rd.yahoo.com - December 6 at 11:45 AM
marketexclusive.com logoNew Phase IV Data On VBI Vaccines, Inc. (NASDAQ:VBIV) HBV Vaccine Show It Can Carve Out A Market From GlaxoSmithKline plc (ADR) (NYSE:GSK) (NASDAQ:VBIV)
marketexclusive.com - November 14 at 12:28 PM
marketwired.com logoVBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac™ Hepatitis B Vaccine (NASDAQ:VBIV)
www.marketwired.com - November 14 at 12:28 PM
insidermonkey.com logoNew Phase IV Data On VBI Vaccines, Inc. (VBIV) HBV Vaccine Show It Can Carve Out A Market From GlaxoSmithKline PLC (ADR) (GSK) (NASDAQ:VBIV)
www.insidermonkey.com - November 14 at 12:28 PM
finance.yahoo.com logoTrump Victory Gives Life to Pharma,Biotech - Take a Look at VBI Vaccines (NASDAQ:VBIV)
finance.yahoo.com - November 11 at 7:57 PM
finance.yahoo.com logoVBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting (NASDAQ:VBIV)
finance.yahoo.com - November 10 at 11:49 AM
thestreet.com logoLikely Clinton Victory Has Created an Opportunity for This Stock (NASDAQ:VBIV)
www.thestreet.com - November 7 at 9:12 PM
News IconWhy Entrepreneurs Are Getting Serious About Biotech (NASDAQ:VBIV)
www.inc.com - November 3 at 12:33 PM
finance.yahoo.com logoVBI Vaccines to Present Zika Vaccine Program Poster at the Keystone Symposia on Translational Vaccinology for Global Health (NASDAQ:VBIV)
finance.yahoo.com - October 27 at 10:33 AM
streetinsider.com logoVBI Vaccines (VBIV) Says Pre-IND Meeting with FDA Over VBI-1901 Complete; Fast-Track Designation Under Consideration (NASDAQ:VBIV)
www.streetinsider.com - October 13 at 11:56 AM
huffingtonpost.com logoSome of the Biotech Industry's Most Recognized Investors Are Focusing on the Zika Vaccine (NASDAQ:VBIV)
www.huffingtonpost.com - October 13 at 11:56 AM
finance.yahoo.com logoVBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate (NASDAQ:VBIV)
finance.yahoo.com - October 11 at 7:42 PM
finance.yahoo.com logoVBI Vaccines to Present at the World Vaccine Congress Europe (NASDAQ:VBIV)
finance.yahoo.com - October 5 at 7:46 PM
marketwired.com logoVBI Vaccines to Present at the Ladenburg Thalmann Healthcare Conference (NASDAQ:VBIV)
www.marketwired.com - September 28 at 7:41 PM
finance.yahoo.com logoVBI Vaccines Announces Results of Annual General and Special Meeting (NASDAQ:VBIV)
finance.yahoo.com - September 26 at 7:57 PM
fxpips.com logoTop Manufacturing Stocks Daily List (NASDAQ:VBIV)
www.fxpips.com - September 22 at 7:25 AM
News IconVBI’s Sci-B-Vac Should Take Market Share In The Hepatitis B Vaccine Market (NASDAQ:VBIV)
www.ssuchronicle.com - September 22 at 7:25 AM
finance.yahoo.com logoVBI's Sci-B-Vac Should Take Market Share In The Hepatitis B Vaccine Market (NASDAQ:VBIV)
finance.yahoo.com - September 21 at 7:28 PM
rttnews.com logoMSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT (NASDAQ:VBIV)
www.rttnews.com - September 21 at 11:47 AM
finance.yahoo.com logoVBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of Its Preventative Cytomegalovirus Vaccine Candidate (NASDAQ:VBIV)
finance.yahoo.com - September 21 at 11:47 AM
marketwired.com logoVBI Vaccines to Present at the Rodman & Renshaw Annual Global Investment Conference (NASDAQ:VBIV)
www.marketwired.com - September 7 at 8:03 PM
finance.yahoo.com logoVBI Vaccines: The Safer Alternative to the Struggling Dynavax Technologies (NASDAQ:VBIV)
finance.yahoo.com - September 6 at 7:37 AM
marketwired.com logoVBI Vaccines to Present at the Vaccine Congress (NASDAQ:VBIV)
www.marketwired.com - September 1 at 7:56 PM
marketwired.com logoVBI Vaccines to Present at the Immuno-Oncology Summit (NASDAQ:VBIV)
www.marketwired.com - August 31 at 7:52 AM
finance.yahoo.com logoAn In-Depth Look at the VBI Vaccines CMV Study (NASDAQ:VBIV)
finance.yahoo.com - August 25 at 8:21 PM
finance.yahoo.com logoVBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review (NASDAQ:VBIV)
finance.yahoo.com - August 25 at 7:41 AM
thestreet.com logoDoes This Under-the-Radar Company Hold the Key to a Zika Vaccine? (NASDAQ:VBIV)
www.thestreet.com - August 9 at 8:27 PM
seekingalpha.com logoUnderstanding The Zika Virus And Which Companies Are Working To Eliminate The Problem (NASDAQ:VBIV)
seekingalpha.com - July 31 at 7:23 PM
finance.yahoo.com logoCoverage initiated on VBI Vaccines by Ladenburg Thalmann (NASDAQ:VBIV)
finance.yahoo.com - July 26 at 7:41 AM
marketwired.com logoVBI Vaccines Appoints Dr. Francisco Diaz-Mitoma as Chief Medical Officer (NASDAQ:VBIV)
www.marketwired.com - July 25 at 8:17 PM
marketwired.com logoVBI Vaccines Applies its eVLP Platform in the Development of a Novel Vaccine Candidate to Prevent Zika Virus (NASDAQ:VBIV)
www.marketwired.com - July 19 at 9:00 AM
publicnow.com logoResearchers Explore the Mechanisms by Which CMV Infection May Impact Fetal Brain Development (NASDAQ:VBIV)
www.publicnow.com - July 14 at 9:28 AM
finance.yahoo.com logoGetting to Know VBI Vaccines (NASDAQ:VBIV)
finance.yahoo.com - July 13 at 1:04 PM
gurufocus.com logoGetting To Know VBI Vaccines Inc. (VBIV) (NASDAQ:VBIV)
www.gurufocus.com - July 12 at 8:20 PM
finance.yahoo.com logoVBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate (NASDAQ:VBIV)
finance.yahoo.com - June 23 at 10:39 AM
finance.yahoo.com logo8:38 am VBI Vaccines closes private placement of ~3.27 mln shares of common stock at ~$4.16/share for total gross proceeds of ~$13.6 mln (NASDAQ:VBIV)
finance.yahoo.com - June 21 at 8:38 AM
finance.yahoo.com logoVBI Vaccines Announces Closing of $13.6 Million Private Placement (NASDAQ:VBIV)
finance.yahoo.com - June 21 at 8:30 AM
publicnow.com logoVBI Vaccines Announces Medulloblastoma Immunotherapy Program (NASDAQ:VBIV)
www.publicnow.com - June 17 at 8:39 AM
finance.yahoo.com logoVBI Vaccines to Present at the Virus-Like Particle and Nano-Particle Vaccines Conference (NASDAQ:VBIV)
finance.yahoo.com - June 17 at 8:30 AM

Social

What is VBI Vaccines, Inc. -'s stock symbol?

VBI Vaccines, Inc. - trades on the NASDAQ under the ticker symbol "VBIV."

Where is VBI Vaccines, Inc. -'s stock going? Where will VBI Vaccines, Inc. -'s stock price be in 2017?

2 equities research analysts have issued 12-month price targets for VBI Vaccines, Inc. -'s shares. Their predictions range from $6.00 to $6.00. On average, they anticipate VBI Vaccines, Inc. -'s stock price to reach $6.00 in the next year.

Who owns VBI Vaccines, Inc. - stock?

VBI Vaccines, Inc. -'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (17.96%).

Who bought VBI Vaccines, Inc. - stock? Who is buying VBI Vaccines, Inc. - stock?

VBI Vaccines, Inc. -'s stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC.

How do I buy VBI Vaccines, Inc. - stock?

Shares of VBI Vaccines, Inc. - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of VBI Vaccines, Inc. - stock cost?

One share of VBI Vaccines, Inc. - stock can currently be purchased for approximately $4.78.

VBI Vaccines, Inc. - (NASDAQ:VBIV) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for VBI Vaccines, Inc. - (NASDAQ:VBIV)

Earnings History Chart

Earnings by Quarter for VBI Vaccines, Inc. - (NASDAQ:VBIV)

Dividend History Chart

Dividend Payments by Quarter for VBI Vaccines, Inc. - (NASDAQ:VBIV)

Last Updated on 2/27/2017 by MarketBeat.com Staff